Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation.

Eculizumab aHUS thrombotic microangiopathy

Journal

Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300

Informations de publication

Date de publication:
Historique:
entrez: 1 8 2020
pubmed: 9 5 2019
medline: 9 5 2019
Statut: epublish

Résumé

Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient outcome. We present a patient who developed recurrent aHUS after kidney transplantation that responded to eculizumab therapy. A kidney biopsy was performed to confirm resolution of thrombotic microangiopathy 8 weeks after eculizumab treatment initiation and revealed no features of thrombotic microangiopathy. Instead, the biopsy revealed monoclonal immunoglobulin G (IgG)4/2κ deposition in the glomerular tufts, vasculature, and atrophic tubular basement membranes. IgG4/2κ deposits are a rare pathologic finding following eculizumab therapy, and the long-term effect of these deposits on kidney function remains unknown.

Identifiants

pubmed: 32734194
doi: 10.1016/j.xkme.2019.03.005
pii: S2590-0595(19)30030-5
pmc: PMC7380410
doi:

Types de publication

Case Reports

Langues

eng

Pagination

139-143

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL132325
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 The Authors.

Références

Mol Immunol. 1996 Dec;33(17-18):1389-401
pubmed: 9171898
Am J Kidney Dis. 2017 Nov;70(5):715-721
pubmed: 28720207
Ultrastruct Pathol. 2016;40(1):2-6
pubmed: 26512451
J Am Soc Nephrol. 2012 Jul;23(7):1229-37
pubmed: 22677550
Am J Hematol. 2010 Aug;85(8):553-9
pubmed: 20658586
N Engl J Med. 2006 Sep 21;355(12):1233-43
pubmed: 16990386
Intractable Rare Dis Res. 2014 May;3(2):34-45
pubmed: 25343125
Hum Mutat. 2010 Jun;31(6):E1445-60
pubmed: 20513133
J Immunoassay Immunochem. 2017;38(2):178-189
pubmed: 27617501
J Am Soc Nephrol. 2001 Jul;12(7):1482-92
pubmed: 11423577
Diagn Pathol. 2016 Oct 7;11(1):94
pubmed: 27717365
J Blood Med. 2016 Apr 12;7:39-72
pubmed: 27110144

Auteurs

Priyamvada Singh (P)

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA.
Transplant Nephrology Section, Department of Medicine, Ohio State University, Columbus, OH.

Hui Chen (H)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston, MA.

Craig E Gordon (CE)

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA.

Sandeep Ghai (S)

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA.

J Mark Sloan (JM)

Hematology, Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, MA.

Karen Quillen (K)

Hematology, Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, MA.

Sara Moradi (S)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston, MA.

Vipul Chitalia (V)

Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA.
Whitaker Institute, Boston University School of Medicine, Boston, MA.

Amitabh Gautam (A)

Department of Surgery, Boston University School of Medicine, Boston, MA.

Joel Henderson (J)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston, MA.

Jean M Francis (JM)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston, MA.

Classifications MeSH